Zevra Therapeutics announces final CHMP opinion on arimoclomol for NPC in EU
FROM THE WIRE · MANILATIMES.NET
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe negative CHMP opinion weighs on the drug's European prospects for the company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The final CHMP opinion on arimoclomol for Niemann-Pick disease type C is negative.
- 02The European Commission will make the final decision on the marketing authorisation application.
- 03The decision concerns treatment of NPC in the European Union.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets